We are live on ! Find out more
BOLD

Boundless Bio
BOLD

Fund managers haven’t disclosed any holdings of BOLD yet.

BOLD Hedge Fund Activity: Q1 2026 in Review

36 of the 8,139 institutional investors tracked by Wall St. Rank reported a position in Boundless Bio (BOLD) for Q1 2026, worth a combined $9.33M — down 11% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BOLD positions and 6 closed out — a net gain of 1 holder — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $67.4K. The largest seller was Northern Trust, exiting entirely with an estimated $227K sold.

  • 36 institutional investors held Boundless Bio (BOLD) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $9.33M of Boundless Bio stock for Q1 2026, down 11% quarter-over-quarter.
  • 7 funds opened new Boundless Bio positions in Q1 2026 and 6 closed out, a net change of +1 holder.
  • The largest Boundless Bio buyer in Q1 2026 was Renaissance Technologies, an estimated $67.4K added.
  • The largest Boundless Bio seller in Q1 2026 was Northern Trust, an estimated $227K sold.

Based on aggregated 13F filings for Q1 2026.